Business Description
SynAct Pharma AB
ISIN : SE0008241491
Total Employee Number:
8Compare
Compare
Traded in other countries / regions
SYNACT.Sweden8F8.GermanySYNACs.UK IPO Date
2021-05-04Description
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 61.42 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.4 | |||||
3-Year EPS without NRI Growth Rate | 15.3 | |||||
3-Year FCF Growth Rate | 23.3 | |||||
3-Year Book Growth Rate | -8.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.2 | |||||
9-Day RSI | 64.32 | |||||
14-Day RSI | 61.73 | |||||
3-1 Month Momentum % | -18.96 | |||||
6-1 Month Momentum % | -37.16 | |||||
12-1 Month Momentum % | -24.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.87 | |||||
Quick Ratio | 4.87 | |||||
Cash Ratio | 3.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.2 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -59.6 | |||||
ROA % | -47.51 | |||||
ROIC % | -66.48 | |||||
3-Year ROIIC % | -7.61 | |||||
ROC (Joel Greenblatt) % | -3837.19 | |||||
ROCE % | -55.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.22 | |||||
PB Ratio | 5.47 | |||||
Price-to-Tangible-Book | 24.17 | |||||
EV-to-EBIT | -8.36 | |||||
EV-to-EBITDA | -8.36 | |||||
EV-to-Forward-EBITDA | -10.87 | |||||
EV-to-FCF | -9.8 | |||||
| Price-to-Net-Current-Asset-Value | 24.17 | |||||
| Price-to-Net-Cash | 56.4 | |||||
Earnings Yield (Greenblatt) % | -11.96 | |||||
FCF Yield % | -9.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SynAct Pharma AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -4.608 | ||
| Beta | 2.004 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.42 | ||
| Volatility % | 50.01 | ||
| 14-Day RSI | 61.73 | ||
| 14-Day ATR (€) | 0.100654 | ||
| 20-Day SMA (€) | 1.34695 | ||
| 12-1 Month Momentum % | -24.32 | ||
| 52-Week Range (€) | 0.968 - 2.32 | ||
| Shares Outstanding (Mil) | 56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SynAct Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SynAct Pharma AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 45 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 45 days | ||
| General meeting for 2026 | 2026-06-11 11:00 | 1.27 (-1.85%) | ||
| First quarter earnings results for 2026 | 2026-05-27 | 1.30 (-0.46%) | ||
| Annual report for 2025 | 2026-04-15 | 1.60 (+0.75%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-18 | 1.66 (-1.65%) | ||
| Third quarter earnings results for 2025 | 2025-10-30 | 1.93 (+3.20%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | 1.58 (-0.13%) |
Show
Entries
SynAct Pharma AB Frequently Asked Questions
What is SynAct Pharma AB(FRA:8F8)'s stock price today?
The current price of FRA:8F8 is €1.69. The 52 week high of FRA:8F8 is €2.32 and 52 week low is €0.97.
When is next earnings date of SynAct Pharma AB(FRA:8F8)?
The next earnings date of SynAct Pharma AB(FRA:8F8) is 2026-08-20.
Does SynAct Pharma AB(FRA:8F8) pay dividends? If so, how much?
SynAct Pharma AB(FRA:8F8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on SynAct Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers